Fig. 8.
Changes in EBV load in 2 patients whose tumor progressed with rituximab therapy.
Patients P1 and P6 (panels A and B), both of whom had active PTLD and failed conventional treatment, received 4 weekly infusions of rituximab at the dose of 375 mg/m2. Blood was drawn at the indicated time points and PBMCs were isolated. Viral loads were determined by QC-PCR on DNA extracted from 1 × 106PBMCs. Despite the quick decrease in peripheral blood EBV loads, PTLD tumors in both patients progressed.
